BioNTech partners with CEPI to advance development of mpox vaccine – ET HealthWorld | Pharma


Bengaluru: Germany’s BioNTech said on Monday it is entering into a partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) to advance the development of its mpox vaccine.

CEPI will provide funding of up to $90 million to support the development of vaccine candidates which is based on BioNTech’s mRNA technology.

BioNTech will initiate a early-to-mid stage trial for the vaccine BNT166 for the prevention of mpox.

Mpox is a viral illness which causes skin rashes and can be transmitted to humans through physical contact.

The partnership is part of BioNTech’s strategy to develop vaccines for the prevention of high-medical-need infectious diseases, including diseases that disproportionally affect lower-income countries, the company said.

  • Published On Sep 19, 2023 at 01:21 PM IST

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

Download ETHealthworld App

  • Get Realtime updates
  • Save your favourite articles

Scan to download App

Source link

Like it? Share with your friends!



Your email address will not be published. Required fields are marked *